remdesevir - for COVID-19 method

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA
clinical improvement 1.30 [1.12, 1.51]> 10%2 studies (2 / -)100.0 %some concernnot evaluable moderatecrucial-
clinical improvement (14-day) 1.21 [0.64, 2.28]> 10%1 study (1 / -)71.9 %lownot evaluable highcrucial-
clinical improvement (28-day) 1.37 [0.79, 2.39]> 10%1 study (1 / -)86.8 %lownot evaluable highcrucial-
clinical improvement (7-day) 0.99 [0.18, 5.51]> 10%1 study (1 / -)49.4 %lownot evaluable highcrucial-
clinical improvement (time to event analysis only) 1.23 [0.87, 1.74]> 10%1 study (1 / -)87.7 %lownot evaluable highcrucial-
deaths 0.77 [0.54, 1.09]< 10%2 studies (2 / -)93.0 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.70 [0.47, 1.04]< 10%1 study (1 / -)96.1 %some concernnot evaluable moderatecrucial-
AE leading to drug discontinuation 2.43 [0.79, 7.45]< 10%1 study (1 / -)6.0 %lownot evaluable highimportant-
serious adverse events 0.71 [0.55, 0.92]< 10%2 studies (2 / -)99.5 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 2 pathologies: 87,95,94,90,91,97 91, 94